Uncovering the hidden impact

Life with PsA and axSpA isn’t always what it seems

I always say I’m fine when people ask. I mean, who wants to hear the truth?”

—Patient living with axSpA

PsA and axSpA are complex and challenging diseases, and the burden on patients is substantial.1 However, the true impact of PsA and axSpA on a patient’s health, wellbeing and quality of life is often underreported and underestimated.1–5

Despite therapeutic advances, just one-third of patients with PsA and axSpA achieve the target level of disease control* six months into biologic treatment.6,7 Even among patients who achieve low levels of disease activity, many still experience a significant residual burden, including pain, limited physical function and poor mental wellbeing.8

It is widely understood that the symptoms of PsA and axSpA can impair a patient’s ability to carry out daily activities, participate socially and work productively.1,9–12

But just how deep is this hidden impact and how many patients does it affect?

Everyday activities

of people with axSpA feared being unable to carry out daily tasks due to their disease.**13

Work and career

of people living with PsA reported a moderate or major impact of PsA on their work productivity.†14

Sleep

of people living with axSpA have moderate to severe insomnia.‡15

Social life and relationships

of participants admitted that they had stopped participating in social activities as a result of PsA.†14

Uncover more insights into the remaining unmet needs of patients with PsA and axSpA

UCB

The reality of Life with PsA and axspa

UCB

Understand the challenge

UCB

Ask one more question

Abbreviations

AS, ankylosing spondylitis; ASDAS-ID, Ankylosing Spondylitis Disease Activity Score-inactive disease; axSpA, axial spondyloarthritis; EMAS, European Map of Axial Spondyloarthritis; PsA, psoriatic arthritis

Footnotes

*As measured by minimal disease activity in PsA and clinical remission as defined by ASDAS-ID in axSpA, according to clinical trial and real-world data. 6,7

**Results from EMAS survey of 638 patients with axSpA in 2018.13

†Results from The Harris Poll online global survey of 1286 patients conducted in Australia, Brazil, Canada, France, Spain, Taiwan, the UK and the US in 2017 and 2018. Participants responded to the question, “How much of a negative impact, if any, has psoriatic arthritis had on your work productivity (no impact/slight/moderate/major)?”14

‡Data from a study in Morocco that included 110 patients with AS.16

References

1. Garrido-Cumbrera M, et al. Rheumatol Ther. 2017;4(2):219–231. 2. Lim I, et al. Rheumatol Ther. 2021;8:761–774. 3. Chisholm A, et al. Rheumatology (Oxford). 2016;55(6):1047–1052. 4. UCB Data on file. Fernando et al. 2022. UCB correspondence . 5. Husni ME, et al. Arthritis Res Ther. 2018;20(1):102. 6. Zardin-Moraes M, et al. J Rheumatol. 2020;47(6):839–846. 7. Ørnbjerg LM, et al. Ann Rheum Dis. 2019;78:1536-1544. 8. Liu V, et al. J Rheumatol. 2021;48(5):677–84. 9. Coates LC, et al. Rheumatol Ther. 2021;8(4):1741–1758. 10. Garrido-Cumbrera M, et al. Curr Rheumatol Rep. 2019;21:19. 11. Garrido-Cumbrera M, et al. Ann Rheum Dis. 2020;79:1134–1135. 12. Macfarlane GJ, et al.J Rheumatol. 2019;46(2):145–152. 13. Gossec L, et al. Ann Rheum Dis. 2019;78:1243–1244. 14. Coates LC, et al. Health Qual Life Outcomes. 2020;18(1):173. 15. Strand V, Singh JA. J Clin Rheumatol. 2017;23(7):383–391. 16. Aissaoui N, et al. Rheumatol Int. 2012;32(7):2117–2124.

GL-N-DA-RH-2200023

Date of preparation: May 2022

Intended for healthcare professionals